Identification of novel mutant PAX6 alleles in Indian cases of familial aniridia

Guruswamy Neethirajan1, Jeyabalan Nallathambi1, Subbaiah Ramasamy Krishnadas2, Perumalsamy Vijayalakshmi3, Shetty Shashikanth3, Jon Martin Collinson4 and Periasamy Sundaresan*1

Address: 1Department of Genetics, Aravind Medical Research Foundation, Madurai, India, 2Department of Glaucoma, Aravind Eye Hospital, Madurai, India, 3Department of Pediatric Ophthalmology and Strabismus, Aravind Eye Hospital, Madurai, India and 4School of Medical Sciences, University of Aberdeen, Aberdeen, UK

Email: Guruswamy Neethirajan - neethirajan@rediffmail.com; Jeyabalan Nallathambi - nallathambi@aravind.org; Subbaiah Ramasamy Krishnadas - krishnadas@aravind.org; Perumalsamy Vijayalakshmi - pvijayalakshmi@aravind.org; Shetty Shashikanth - drshashikants@yahoo.com; Jon Martin Collinson - m.collinson@abdn.ac.uk; Periasamy Sundaresan* - sundar@aravind.org

* Corresponding author

Abstract

Background: Haploinsufficiency at the PAX6 locus causes aniridia, a panocular eye condition characterized by iris hypoplasia and a variety of other anterior and posterior eye defects leading to poor vision. This study was performed to identify novel PAX6 mutations that lead to familial aniridia in Indian patients.

Methods: Genomic DNA was isolated from affected individuals (clinically diagnosed aniridia) from nine unrelated aniridic pedigrees, unaffected family members, and unrelated normal controls. The coding regions of PAX6 were amplified and subjected to single strand conformation polymorphism (SSCP) gel analysis, and direct cloning and sequencing.

Results: SSCP band shifts, indicative of DNA base pair mutations, were observed in five of these unrelated families. Four mutations were shown to be previously unreported insertion or deletions in PAX6, leading to frameshifts. These new mutations were c.1174delTG (in exon 10), c.710delC (exon 6), c.406delTT (exon 5) and c.393insTCAGC (exon 5). The other nonsense mutation, a transition (c.1080C>T) in exon 9, has been reported previously as a mutation hotspot for PAX6 in other ethnic pedigrees. All mutant alleles transmitted through aniridic individuals in each family.

Conclusion: These new deletions and an insertion create frameshifts, which are predicted to introduce premature termination codons into the PAX6 reading frame. The genetic alterations carried by affected individuals are predicted to lead to loss-of-function mutations that would segregate in an autosomal dominant manner to subsequent generations. This is the first report of the 'hotspot' c.1080C>T transition from Indian families.
Background
Congenital absence of the iris is known as aniridia in humans. Aniridia is mostly a panocular defect leading to anterior and posterior segment defects that are associated with isolated cataracts, macular hypoplasia, keratits, and Peter’s anomaly [1]. One third of cases are sporadic and two thirds are familial with an autosomal dominant mode of inheritance with high penetrance [2]. PAX6, from chromosome band 11p13, was identified as the candidate gene for aniridia by positional cloning [3]. PAX6 is widely expressed in the developing eye and is one of the master control genes in eye development. Molecular genetics studies have revealed that autosomal dominant aniridia results from many possible mutations in the PAX6 gene [4-7]. The PAX6 gene spans 22 kb and consists of 14 exons. The translation initiation codon is in exon 4 and the termination codon is in exon 13 [4]. The human PAX6 gene has paired box and homeobox motifs that encode a highly conserved protein of 422 amino acids among metazoans. The paired domain and the homeodomain are DNA binding domains, and are separated by a linker segment (LNK) and followed by a C-terminal region rich in proline, serine and threonine (PST). PAX6 functions as a transcription factor to regulate the expression of other genes during embryogenesis and in the adult eye [8]. Mutations in the PAX6 gene have so far been described in sporadic cases from India [6,7], but there was no previous report on mutations in Indian familial aniridia. We therefore present an analysis of five Indian pedigrees out of nine with hereditary aniridia demonstrating four novel mutations and one previously reported nonsense genetic alteration of PAX6.

Methods
Clinical evaluation and proband selection
The study protocol adhered to the tenets of the Declaration of Helsinki. After providing informed consent, nine unrelated clinically diagnosed inherited aniridia families (ANF1 to ANF9) with their available unaffected members and 60 healthy non-aniridic unrelated normal controls were recruited for this study. Ophthalmic specialists selected these families in the first instance because of iris absence, and classical aniridia was confirmed by the presence of secondary eye defects consistent with aniridia, and no contraindications. Examination included slit lamp, gonioscopy, intraocular pressure measurement, and biomicroscopy. Peripheral blood samples were collected for isolation of total genomic DNA by salt precipitation from probands, affected, unaffected family members, and normal controls.

Mutation screening and sequence analysis
Exons 4–13 of the human PAX6 gene were amplified using previously described primers [4] in a 20 μl reaction mixture containing 100 ng genomic DNA, 100 pM of each primer, 1X PCR buffer (Promega, USA) and 0.5 U of Taq DNA polymerase (Promega, USA). PCRs were carried out in a MJ Research thermocycler for 35 cycles. PCR conditions were 1 minute at 95°C for denaturation, 1 minute at 58°C for primer annealing and 10 minutes at 72°C for primer extension. The amplified PCR products showing a single band of the correct size were stored at -20°C before electrophoretic analysis. For single-strand conformation polymorphism (SSCP) analysis, approximately 6 μl of the amplified DNA was mixed with 4 μl of denaturing dye (95% formamide, 10 mM NaOH) and run on a 10% polyacrylamide gel with or without 2.5% glycerol. Electrophoresis was carried out for 6 hours at 800 V. The gels were stained with silver nitrate as described previously [6]. Based on the mobility shifts seen on the SSCP gel, exons containing potential mutations were re-amplified and the PCR products were purified by excising the desired band from the agarose gel and eluting using a QIA quick gel extraction kit (QIAGEN Gmbh, Germany). PCR products were either sequenced directly or cloned into pGEM-T (Promega USA). The superimposed mutant PCR products were amplified, ligated, then transformed into E. coli DH5α and plated onto LB agar medium containing ampicillin. Transformed colonies were patched on a different plate for the isolation of plasmids. About 10 individual colonies were picked from each ligation and then plasmids were isolated by alkaline lysis. These plasmids were checked by restriction enzyme digestion and used as templates in PCR reactions for amplification of the insert. The mutants were detected by allele specific clones.

The PCR products were sequenced on Applied Biosystems (ABI) model 3730 automated sequencer (Microsynth, Switzerland) using PCR primers from published literature [4] or universal primers for pDrive (QIAGEN, Germany).

Digestion
Ten microliters of the mutant and normal PCR products were digested in a reaction mixture containing 1X buffer and 10 U of appropriate restriction enzyme (Fermentas, Germany). The reaction was incubated at 37°C for 2 hours and the products were visualized on a 2.5% agarose gel.

PAX6 cDNA numbering
PAX6 cDNA sequences used and mutations were annotated according to the PAX6 Allelic Variant Database [9]. The coding region runs from base 363 (in exon 4) to base 1628 (in exon 13). The PST region extends from base 1169 to base 1628.

Results
We screened for PAX6 mutations in genomic DNA from nine Indian pedigrees with familial aniridia in which more than one person was affected. The probands
Family ANF2: novel mutation c.1174delTG
[Genbank:DQ251040]

Affected individuals from the three-generation family ANF2 showed bands with altered mobility shift on SSCP gels and were shown by sequencing to be heterozygous for the mutation c.1174delTG at codon 271 in exon 10 (Fig. 2A, C). The affected aniridic mother passed the mutation onto two children. This deletion leads to a frameshift, alters a leucine residue (codon 271) and creates a premature termination codon 12 residues downstream. The conformations observed both in genomic DNA and the cloned PCR products showed the same profiles (Fig. 2A, B). The mutation was predicted to alter a Ddel site in exon 10 and the mutation was reconfirmed by Ddel restriction of PCR products from both in unaffected controls and in mutants. The wild-type alleles of unaffected individuals and unrelated controls showed two bands, 160 bp and 83 bp, whereas DNA from the affected individuals yielded 243 bp, 160 bp and 83 bp bands (Fig. 2D), confirming the loss of the Ddel restriction site on one allele of affected individuals in this family.

Family ANF7: novel mutation c.710delC
[Genbank:DQ251039]

In the two generation consanguinous family ANF7 (Fig. 2E) showed aberrant banding patterns on SSCP analysis. Sequencing indicated a deletion mutation c.710delC in all the affected individuals in this family. The conformation profiles of genomic PCR-SSCP and the cloned allele-specific PCR products showed the same pattern (Fig. 2E, F). Deletion of the single cytosine residue (Fig. 2I) is predicted to lead to a frameshift at codon 15 in the paired domain. The PCR product of the unaffected father showed a wild-type allele of PAX6 (Fig. 2H).

Family ANF8: novel mutation c.393ins5
[Genbank:DQ251037]

The mutation in another three generation family ANF8 was originally detected by SSCP in exon 5 (Fig. 4A, B) of the paired domain and was further analyzed by sequencing the PCR product of affected individuals and unaffected relatives from the family. The DNA sequence of the PCR product of affected heterozygous individuals showed a 5 base pair insertion duplication (TCAGC) at c.393ins5 (codon 11) (Fig 4C, D). This results in a frameshift mutation at a leucine residue, which produces a premature termination codon 20 codons distal to the mutation location, in exon 5 within the paired domain. The male ANF8-1 had sudden loss of vision at age 11 and anterior segment examination revealed bilateral microcornea with aniridic keratopathy. Another affected 8-year old female ANF8-3 also had microcornea with post polar cataract in the right eye.

Five mutations in the coding regions have therefore been documented in the family study, in which we have identified four novel mutant PAX6 alleles in Indian familial aniridic patients.
Discussion

Most familial aniridia patients have mutations within PAX6 that are dominantly inherited with high penetrance. Sporadic cases are likely to have de novo mutations in PAX6, and expected to be transmitted to the next generation in an autosomal dominant fashion. In this study, we observed several novel PAX6 mutations in familial aniridia. Affected family members in at least two generations carry the mutant alleles.

SSCP is an easy, but perhaps inefficient method to screen for mutations in genomic DNA. In this study, five mutations were found in PAX6 in affected members from nine unrelated families with inherited aniridia. All the mutations were identified initially based on aberrant bands on SSCP gels that differed from the normal allelic patterns shown by unaffected family members. Each mutation was only found in affected individuals.

Table 1: Clinical information of familial aniridia patients

| Patient          | Best Vision | Refractive Error | Nystagmus | Keratopathy | Iris Cataract | Glaucoma | Fovea Hypoplasia | Macular Hypoplasia | Treatment |
|------------------|-------------|------------------|-----------|--------------|---------------|----------|------------------|---------------------|-----------|
|                  | R L R L     | R L R L R       | R L R     | L R L R L R L | R L R L R L R | R L R L | R L R L R L R L | R L R L R L R L | R L R L |
| ANF2-1 F (5)     | CF          | 6/60 -           | -5.0-2.0  | + +          | - R           | + + +   | + +              | + +                 | 1.2 1     |
| ANF2-3 M (11)    | PL          | 5/60 -           | +10 +     | + +          | - R           | + + +   | + +              | + +                 | - + 1.2 |
| ANF2-2 F (28)    | PL          | 3/60 -2.0        | -         | + + A        | + A           | + +     | + +              | + +                 | -        |
| ANF6-I F (10)    | 4/60 6/36   | 2.0              | + + A     | + A          | + A           | + + +   | + +              | + +                 | - + - |
| ANF6-F (24)      | 3/60 6/36   | +11 +11.5        | +         | + A          | + A           | - -     | - -              | + +                 | - + - |
| ANF7-I M (0.5)   | NA          | -                | +         | - - R        | - -           | + +     | + +              | + +                 | - + - |
| ANF7-2 F (22)    | 6/18 PL     | +11 +        | +         | + A          | + A           | + +     | + +              | + +                 | - + - 2 |
| ANF9-1 F (5)     | 6/24 6/24   | -4.0 -4.0       | +         | A + A        | A + A         | - -     | - -              | + +                 | - + - |
| ANF9-2 M (39)    | 3/60 3/60   | -2.0 -2.5       | +         | A + A        | A + A         | - -     | - -              | + +                 | - + - |
| ANF8-1 M (12)    | PL          | -                | +         | + A          | + A           | - -     | - -              | + +                 | - + - |
| ANF8-2 M (45)    | 6/36 6/36   | +1.5 +1.5       | +         | A A          | A A           | - -     | - -              | + +                 | - + - |
| ANF8-3 F (8)     | PL          | -                | +         | A A          | A A           | - -     | - -              | + +                 | - + - |

Key: PL, perception of light; CF, counting fingers; A, absent; R, remnant; NA, not applicable; I, trabeculectomy; 2, cataract surgery

Many mutations in PAX6 generating premature termination codons have been previously reported [10] and are deposited in the Human PAX6 Allelic Variant Database [9]. A c.1080C>T change (R240X), identical to that in our family ANF6, that was identified recently in a Thai study also showed complete aniridia with nystagmus, strabismus and foveal hypoplasia [10]. c1080C>T has been reported several times previously in other ethnic groups and appears to represent a hotspot of PAX6 mutation, perhaps due to methylated cytosine deamination. The ... in ANF8-1 is novel, but a c.395delC mutation with familial aniridia was previously reported which lies in same codon of PAX6 but two base pairs down [12].

The mutant mRNAs predicted by this study are likely to be detected by RNA surveillance and degraded by nonsense-mediated decay [13,14], and hence we predict that they will all represent loss-of-function mutations.

Table 2: Summary of genetic variation in familial aniridic patients

| No | Systematic Name | Codon | Exon/Intron | Domain | Common Name patient ID | Type of Mutation | Interpretation | Gene bank Accession No. |
|----|----------------|-------|-------------|--------|------------------------|------------------|----------------|-------------------------|
| 01 | c.1080 C>T     | R240X | exon 9      | Homeodomain | ANF6-1 female | Premature termination | Arginine to stop codon | -- |
| 03 | c.1174delTG    | 271   | exon 10     | PST region | ANF2-1 female | Deletion | Novel mutation | DQ251040 |
| 05 | c.710delC      | 116   | exon 6      | Paired domain | ANF7-1 male | Deletion | Novel mutation | DQ251038 |
| 07 | c.406delTT     | 15    | exon 5      | Paired domain | ANF9-1 male | Insertion | Novel mutation | DQ251037 |
| 09 | c.393insS      | 11    | exon 5      | Paired domain | ANF8-1 | Insertion | Novel mutation | -- |

Key: C, cytosine; T, thymine; PST, posterior segment; R240X, Arginine to Stop codon; Del, Deletion.
Conclusion

Our genetic analysis provides further examples of PAX6 haploinsufficiency leading to aniridia. We report four novel frameshift mutations and one nonsense mutation in Indian aniridic pedigrees. This is the first genetic analysis of familial aniridia in Indian populations and contributes to our understanding of the relationship between PAX6 genotype and ocular phenotype.

Figure 1
Detection of a nonsense mutation (R240X) in the two-generation family ANF6. A- Pedigree showing the affected (dark filled) and unaffected (unfilled) family members. Cloned gPCR product digested with Avai restriction enzyme confirms heterozygosity for the mutation in affected individuals (band sizes 206 bp, 131 bp, 75 bp in lane 2, 3) whereas the unaffected members carry only normal alleles with digested bands at 131 bp and 75 bp (lane 1 and 4). The unrelated normal control is shown on the left (UN). Undigested PCR product is on the right (UD). B- Normal chromatogram of PAX6 shows the presence of CGG (arginine) in exon 9. C- Direct sequencing of the genomic PCRs of the affected mother and (D) affected proband showing the presence of mutation, X-represents stop codon.

Figure 2
Mutation analysis of two unrelated families, ANF2 and ANF7. A. SSCP gel stained with silver nitrate showing unaffected members (2–4, 2–5) and the unusual band shift in affected members (2–1, 2–2), and normal bands in an unrelated unaffected control (lane 1). B. Identical banding patterns were obtained from the cloned mutant (M) and the genomic mutant (G) DNA on silver stained polyacrylamide gels. N represents normal alleles. C. Three generation aniridic pedigree showing the affected and unaffected members and sequencing results of cloned mutant alleles showing the mutant (c.1174delTG) and wild-type alleles of exon 10. D. Restriction digestion analysis: PCR products of the family ANF2 showed heterozygosity (2–1, 2–2) for the mutant allele (243 bp, 160 bp and 83 bp). The wild type shows bands at 160 bp and 83 bp (2–4, 2–5, UN) when digested with Ddel. UN represents an unaffected control. UD represents undigested PCR product of exon 10. E. Polyacrylamide gel showing the bandshift in affected members (7–1, 7–2) but no shift on normal family members or unrelated controls (UN, 7–3, 7–4) of family ANF7. F. Allele specific clones were isolated to confirm the correct clone (M) compared with genomic PCR (G). G. The pedigree showing the two-generation aniridic family (filled-affected, unfilled-unaffected). H. Sequence of the unaffected father showing wild type PAX6. I. Sequencing of cloned alleles revealed the presence of single cytosine residue deletion in exon 6 in the mutants.
Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
GN carried out the molecular genetic analysis. JN assisted in techniques. SRK, PV, and SS contributed for the clinical diagnosis of patients. PS conceived the study carried out the molecular analysis and drafted the manuscript with GN. JMC critically reviewed the study, provided intellectual input, revised and formatted the manuscript. JMC drafted the final version of the manuscript.

Acknowledgements
The authors are very thankful to the participants in this study. The Indian Council of Medical Research (ICMR), New Delhi, India, financially supported this study. JMC is funded by Newlife (Birth Defects Foundation) grant 04/07 and Wellcome Trust grant 074127. The authors also thank the reviewers.

References
1. van Heyningen V, Williamson KA: PAX6 in sensory development. Hum Mol Genet 2002, 11:1161-1167.
2. Nelson LB, Spaeth GL, Nowinski TS, Margo CE, Jackson L: Aniridia: a review. Surv Ophthalmol 1984, 28:621-642.
3. Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T, van Heyningen V, Hastie ND, Meijers-Heijboer H, Drechsler M, Royer-Pokora B, Collins F, Swaroop A, Strong LC, Saunders GF: Positional cloning and characterization of a paired-box and homeobox-containing gene from the aniridia region. Cell 1991, 67:1059-1074.
4. Glaser T, Walton DS, Maas RL: Genomic structure, evolutionary conservation and aniridia mutations in the human PAX6 gene. Nat Genet 1992, 2:232-239.
5. Frosser J, van Heyningen V: PAX6 mutations reviewed. Hum Mutat 1998, 11:93-108.
6. Neethirajan G, Hanson IM, Krishnadass SR, Vijayalakshmi P, Anupkumar K, Sundaresan P: A novel PAX6 gene mutation in an Indian aniridia patient. Mol Vis 2003, 9:205-209.
7. Neethirajan G, Krishnadass SR, Vijayalakshmi P, Shashikant S, Sundaresan P: PAX6 gene variations associated with aniridia in south India. BMC Med Genet 2004, 5:9.
8. Chauhan BK, Reed NA, Zhang W, Duncan MK, Kilmannin MW, Cvekl A: Identification of genes downstream of Pax6 in the mouse lens using cDNA microarrays. J Biol Chem 2004, 277:11539-11548.
9. PAX6 Allelic Variant Database [http://pax6.hgu.mrc.ac.uk/About/pax6cdna.htm]
10. Marsha A, Ferrell RE, Mintz-Hittner H, Lyons LA, Saunders GF: Paired box mutations in familial and sporadic aniridia pre-
dicts truncated aniridia proteins. *Am J Hum Genet* 1994, 54:801-811. Erratum in: *Am J Hum Genet* 1994, 55:602.

11. Atchaneeyasakul L, Trinavarat A, Dulayajinda D, Kumpornsin K, Thongnoppakhun W, Yenchitsomanus P, Limwongse C: Novel and de-novo truncating PAX6 mutations and ocular phenotypes in Thai aniridia patients. *Ophthalmic Genet* 2006, 27:21-27.

12. Wolf MT, Lorenz B, Wintersch A, Dreichler M, Schumacher V, Royer-Pokora B, Blankenagel A, Zabel B, Wildhardt G: Ten novel mutations found in Aniridia. *Hum Mutat* 1998, 12:304-313.

13. Byers PH: Killing the messenger: new insights into nonsense-mediated mRNA decay. *J Clin Invest* 2002, 109:3-6.

14. Vincent MC, Pujo AL, Olivier D, Calvas P: Screening for PAX6 mutations is consistent with haploinsufficiency as the main mechanism leading to various ocular defects. *Eur J Hum Genet* 2002, 11:163-169.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2415/6/28/prepub